Navigation Links
ALPCO Announces the Launch of Rat and Mouse Proinsulin ELISA Kits
Date:1/26/2010

ays, illustrating their utility in the field.  

A hallmark of these new assay systems are their defined cross reactivity with both proinsulin I and II.  Peter Wunderli, PhD, Laboratory Operations Manager at ALPCO, remarks on the significance of this advancement, "Rat proinsulin, as for mouse, is expressed as two isoforms. No one knows whether isoform expression is individually influenced by the disease.  Until that is established, there is a need to be able to measure the total proinsulin.  Our kits do that with excellent specificity and robustness."  

Several factors, not the least of which being the variability in expression of proinsulin I and II between mice and rats, makes the ALPCO species-specific assay kits the most attractive option for researchers expecting to quantify total proinsulin in their pre-clinical models.

While research has established that the total ratio of circulating proinsulin relative to insulin and c-peptide is altered in the diabetic and pre-diabetic state in humans, multiple barriers in the ability to accurately measure rodent proinsulin means relatively limited data has been available regarding concentrations of this molecule in rats and mice, both of which are widely used models in the diabetes research community.  

Craig LaMarca, a scientist and technical sales advisor with ALPCO, stated: "Typically in humans, proinsulin is elevated as a result of impaired processing in the beta cell, which is a characteristic of type 2 diabetes.  In cases of beta cell dysfunction, including type 2 diabetes and pre-diabetes, the proinsulin secretion ratio can increase to >60% (from 5% in a non-diabetic state).  Until now, there has not been a viable method for measuring rodent proinsulin, which would allow researchers to establish models for testing targeted therapies or interventions in the pre-clinical setting.  This ne
'/>"/>

SOURCE ALPCO
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. ALPCO Launches GLP-1 (Active 7-36) and (7-36 and 9-36) ELISA Kits
2. Roxane Laboratories, Inc. Announces the New Drug Application Approval of Morphine Sulfate Oral Solution CII, 100mg/5mL (20mg/mL)
3. Brean Murray, Carret & Co. Announces 2010 Healthcare 1x1 Conference
4. MDS Announces Resolution of Litigation Related to the Sale of MDS Analytical Technologies
5. Agilux Laboratories Announces the Launch of GLP LC/MS/MS Bioanalytical Services
6. ORCS Web, Inc Announces Plans for Employee Ownership
7. Eyre Bus, Tour & Travel Donates Bus to Transport Medical Professionals from D.C. Area to New York for Flight to Haiti, Announces the Greater Washington Haiti Relief Committee and the Embassy of Haiti
8. Forterus Announces Fiscal Year 2009 Financial Results
9. UCLB announces new partnership with Kurma Biofund
10. AXIOM Systems, Inc. Announces General Release of HIPAA 5010 Testing Solutions
11. Universal Health Services, Inc. Announces Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... New York, US (PRWEB) July 10, 2014 ... . , Merrill DataSite recently streamed the live webinar ... featuring a discussion from a group of several M&A ... are seeing in the broader energy transaction marketplace. These ... hot and how the deal market in this sector ...
(Date:7/10/2014)... 2014 CBPartners, a global leader in ... a new website. The redesigned site boasts improved ... to the firm’s thought pieces, blog posts, and conference ... to showcase our insights, capabilities, and to provide timely ... Executive Officer, Cyrus Chowdhury. “An enhanced online presence ...
(Date:7/10/2014)... Best Drug Rehabilitation , which ... close by during a stay in rehab can ... the process is successful, has launched an inspiring ... http://www.bestdrugrehabilitation.com/success-stories/ . , The new Success Stories section ... Best Drug Rehabilitation graduates who wanted to help ...
(Date:7/10/2014)... York (PRWEB) July 10, 2014 ... to protecting the rights of victims injured by ... brought a lawsuit over allegations that the woman’s ... by a power morcellator used during a routine ... filed against Richard Wolf Medical Instruments Corporation over ...
(Date:7/10/2014)... new study from Colorado School of Public Health shows ... a major problem in the Navajo Nation and among ... Americans is abysmal with more than three times the ... Batliner, DDS, MBA, associate director of the Center for ... Health. "The number one problem is access to care." ...
Breaking Medicine News(10 mins):Health News:Register to Download Merrill DataSite's Report: Capitalizing on the Shifting Sands of the Energy Market 2Health News:CBPartners Announces New Website 2Health News:Best Drug Rehabilitation Launches New Success Stories Section of Website 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 3Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 4Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 5Health News:Study finds widespread oral health problems among Navajo 2
... /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals,a developer and manufacturer of ... its financial results for the first quarter,ended March ... the first,quarter of 2008, as compared with $5.2 ... in the first quarter 2008 include wound care ...
... DALLAS, May 6 Claimsnet.com inc. (OTC,Bulletin Board: ... healthcare industry, today reported,its results for the first quarter ... the quarter ended March 31, 2008, the Company reported ... for the first quarter,of 2007., Expenses overall, comprised ...
... U.S. college students are smoking tobacco using waterpipes or ... according to a new study led by a Virginia Commonwealth ... prevalence and perceptions related to waterpipe tobacco smokers and are ... Health. The article is also featured in an editorial in ...
... alleviate the plaguing symptoms of allergies ... and asthma, ... allergies or asthma while outdoors, but why deal with irritating,triggers in your home? ... focus on more important things, not on your,symptoms., Try to prevent as ...
... Acquisition of dermal filler product enhances company,s aesthetic ... Stiefel Laboratories, Inc.,the world,s largest independent pharmaceutical company ... ABR Invent and ABR,Development, developers of the dermal ... of ABR Invent and ABR Development,through a definitive ...
... mole develops into melanoma by showing the interaction of ... The Penn State scientists also demonstrate that therapeutic ... effectively treat this deadly form of cancer. , "We ... Akt3 communicate with one another in a mole, ...
Cached Medicine News:Health News:NUCRYST Announces First Quarter 2008 Financial Results 2Health News:NUCRYST Announces First Quarter 2008 Financial Results 3Health News:NUCRYST Announces First Quarter 2008 Financial Results 4Health News:NUCRYST Announces First Quarter 2008 Financial Results 5Health News:NUCRYST Announces First Quarter 2008 Financial Results 6Health News:NUCRYST Announces First Quarter 2008 Financial Results 7Health News:Claimsnet.com Reports First Quarter 2008 Results 2Health News:Claimsnet.com Reports First Quarter 2008 Results 3Health News:Waterpipe smoking on college campuses may contribute to growing public health problem 2Health News:Double Trouble: Fight Allergy and Asthma in Your Home 2Health News:Stiefel Laboratories, Inc. Acquires ABR Invent and ABR Development 2Health News:Stiefel Laboratories, Inc. Acquires ABR Invent and ABR Development 3Health News:Scientists identify interacting proteins key to melanoma development, treatment 2Health News:Scientists identify interacting proteins key to melanoma development, treatment 3
(Date:7/10/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... the sale to Galderma of all rights to Restylane, ... Valeant for $1.4 billion in cash, pursuant to the ... its acquisition of Galderma. "We are ... a company that is firmly committed to the aesthetic ...
(Date:7/10/2014)... , July 10, 2014  Decision Resources Group ... infectious disease (ID) specialists are willing to prescribe ... (oritavancin) for use as OPAT, approximately two-thirds of ... agents to their hospital inpatients. However, our findings ... patients are initiated on OPAT following hospital discharge, ...
(Date:7/10/2014)... WOONSOCKET, R.I. , July 10, 2014 CVS ... its board of directors has approved a quarterly dividend of ... The dividend is payable on August 1, 2014, to holders ... Caremark CVS Caremark is dedicated to helping ... integrated pharmacy company in the United States ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... ThermoGenesis Corp. (NASDAQ: KOOL ), a ... and administration of cell therapies, today said that it ... Platform (AXP) used for the processing of cord blood. ... in the country later this year. "We ...
... Mass., May 22, 2012  Halo Therapeutics, LLC, a ... fibrotic diseases, announced today that it has received ... serving the muscular dystrophy patient community. Halo will ... study of HT-100, its lead drug candidate for ...
Cached Medicine Technology:ThermoGenesis Announces Axp Approval In Thailand 2ThermoGenesis Announces Axp Approval In Thailand 3Halo Therapeutics Raises $1.1 Million to Expedite Phase 2 Study of HT-100 2Halo Therapeutics Raises $1.1 Million to Expedite Phase 2 Study of HT-100 3
... endoscope is the first Video ... instrument incorporates a 2.0mm instrument ... insertion tube. The slim size ... easy introduction even through areas ...
... Used for temporary internal drainage from ... Supplied sterile in peel-open packages. Intended ... is advised; C-Flex® and Sof-Flex® stents ... six (6) months; silicone stents must ...
... internal drainage from the ureteropelvic junction to ... for ease of placement and patient compliance. ... for repositioning and ease of removal. AQ® ... that when activated, attracts and holds water ...
... Double Pigtail Ureteral Stents have an ... maximizes migration. They also feature unique ... cost savings. Each Classic Double PigTail ... Double PigTail Ureteral Stent with attached ...
Medicine Products: